These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31501860)

  • 1. Facilitating access to new therapeutic options through clinical trials: the vision of a regulator to reconcile innovation and safety.
    Vignot S; Martin M; Albin N; Schurtz C; Chapel E
    Ann Oncol; 2019 Nov; 30(11):1694-1696. PubMed ID: 31501860
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision Medicine in Oncology II: Economics of Targeted Agents and Immuno-Oncology Drugs.
    Huntington SF; Davidoff AJ; Gross CP
    J Clin Oncol; 2020 Feb; 38(4):351-358. PubMed ID: 31804866
    [No Abstract]   [Full Text] [Related]  

  • 3. Perspective on Precision Medicine in Oncology.
    Johnson TM
    Pharmacotherapy; 2017 Sep; 37(9):988-989. PubMed ID: 28632968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-centric trials for therapeutic development in precision oncology.
    Biankin AV; Piantadosi S; Hollingsworth SJ
    Nature; 2015 Oct; 526(7573):361-70. PubMed ID: 26469047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trials as valid therapeutic options for patients with cancer.
    Adashek JJ; LoRusso PM; Hong DS; Kurzrock R
    Nat Rev Clin Oncol; 2019 Dec; 16(12):773-778. PubMed ID: 31477881
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine in oncology: what is it exactly and where are we?
    Le Tourneau C; Kamal M; Bièche I
    Per Med; 2018 Sep; 15(5):351-353. PubMed ID: 30260312
    [No Abstract]   [Full Text] [Related]  

  • 7. [Targeted therapies and immunotherapy: Positioning in the field of innovation and challenges for the therapeutic decision-making process].
    El Chami C; Meunier-Beillard N; Binquet C; Lepage C; Lejeune C
    Bull Cancer; 2024 Oct; 111(10):955-966. PubMed ID: 39209672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pediatric oncology enters an era of precision medicine.
    Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
    Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of neuro-oncology: precision medicine and targeted therapies.
    Waheed A; Rasheed S; Usama M; Chaurasia B
    Neurosurg Rev; 2024 Aug; 47(1):431. PubMed ID: 39141197
    [No Abstract]   [Full Text] [Related]  

  • 10. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.
    Abrams J; Conley B; Mooney M; Zwiebel J; Chen A; Welch JJ; Takebe N; Malik S; McShane L; Korn E; Williams M; Staudt L; Doroshow J
    Am Soc Clin Oncol Educ Book; 2014; ():71-6. PubMed ID: 24857062
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivering on the promise of precision cancer medicine.
    Berger MF; Van Allen EM
    Genome Med; 2016 Oct; 8(1):110. PubMed ID: 27782852
    [No Abstract]   [Full Text] [Related]  

  • 12. Precision medicine beyond medical oncology: using molecular analysis to guide treatments of colorectal neoplasia.
    Molloy MP; Engel A
    Expert Rev Gastroenterol Hepatol; 2018 Dec; 12(12):1179-1181. PubMed ID: 30791786
    [No Abstract]   [Full Text] [Related]  

  • 13. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience.
    Lih CJ; Takebe N
    Curr Probl Cancer; 2017; 41(3):201-211. PubMed ID: 28625332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host-dependent variables: The missing link to personalized medicine.
    Demlova R; Zdrazilova-Dubska L; Sterba J; Stanta G; Valik D
    Eur J Surg Oncol; 2018 Sep; 44(9):1289-1294. PubMed ID: 29735363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision medicine in pediatric oncology.
    Forrest SJ; Geoerger B; Janeway KA
    Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.
    Janiaud P; Serghiou S; Ioannidis JPA
    Cancer Treat Rev; 2019 Feb; 73():20-30. PubMed ID: 30572165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Targeted therapy in the treatment of solid tumors and in hematology-oncology. Advances and disappointments].
    Jochims C; Mazitschek U; Jäger D; Goldschmidt H
    Internist (Berl); 2006 Jun; 47(6):633-41. PubMed ID: 16767478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-Based Precision Oncology with the Cancer Targetome.
    Blucher AS; Choonoo G; Kulesz-Martin M; Wu G; McWeeney SK
    Trends Pharmacol Sci; 2017 Dec; 38(12):1085-1099. PubMed ID: 28964549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From the 2021 ASCO Annual Meeting.
    Killock D
    Nat Rev Clin Oncol; 2021 Aug; 18(8):469. PubMed ID: 34158668
    [No Abstract]   [Full Text] [Related]  

  • 20. The science of precision prevention of cancer.
    Vineis P; Wild CP
    Lancet Oncol; 2017 Aug; 18(8):997-998. PubMed ID: 28759370
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.